• Study of Naxitamab and Sargramostim for High-Risk Neuroblastoma in Patients with Refractory Bone or Bone Marrow Disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Denmark France Germany Italy Spain

  • Study on the Safety and Effects of Ocrelizumab for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy Poland

  • Study on the Effects and Safety of Dupilumab for Children Aged 2 to Under 6 with Uncontrolled Asthma or Severe Asthmatic Wheeze

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia France Germany Greece Hungary Italy +3

  • Study of GLPG3667 for Adults with Active Systemic Lupus Erythematosus

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria France Germany Hungary Poland Spain

  • Study on the Effect of a New Moisturiser with Glycerol and Urea on Skin Barrier in Adults with Atopic Dermatitis

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany

  • Study on the Safety and Effects of ARO-C3 for Adults with Complement-Mediated Kidney Disease

    Not recruiting

    1 1 1
    Investigated Drugs:
    Germany

  • Study on the Safety and Effects of Risdiplam for Adults and Children with Spinal Muscular Atrophy

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Italy The Netherlands Poland

  • Study on the Safety and Effectiveness of Mirabegron for Children Aged 6 Months to Under 3 Years with Neurogenic Detrusor Overactivity

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Denmark Germany Poland

  • Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors

    Not recruiting

    3 1 1
    Investigated Drugs:
    Belgium Czechia Germany Hungary Poland Spain

  • Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Czechia Denmark Finland France +9

powered by